Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;25(9):411–415. doi: 10.1002/clc.4960250904

Cardioversion of atrial fibrillation with ibutilide: When is it most effective?

Mithilesh Kumar Das 1,✉, Kuruvilla Cheriparambil 1, Ashwini Bedi 2, John Kassotis 2, Chatla V R Reddy 2, Barry Saul 2, Majesh Makan 2
PMCID: PMC6653973  PMID: 12269519

Abstract

Background: Atrial fibrillation (AF) is found in 1% of persons above the age of 60 years. More than 5% of the population older than 69 years and about 14% of octogenarians are at risk for this arrhythmia. It is estimated that 1.5 to 3 million persons in the United States alone suffer from AF. The public health implications and attendant morbidity are a significant drain on our health care system.

Hypothesis: The purpose of this study was to determine the clinical and echocardiographic predictors of success in converting AF of ≥ 24 h duration.

Methods: Demographic and clinical and echocardiographic parameters of 101 patients with recent onset AF (> 24 h) who received ibutilide were studied.

Results: Of 101 patients, 56 (55%) converted to sinus rhythm. Age, gender, hypertension, diabetes mellitus, left ventricular ejection fraction (≤ 35%), congestive heart failure, and previous medication for rate control had no significant effect on the conversion rate. Conversion rate was only 30% (9/30 patients) in the presence of an enlarged left atrium (LA > 5 cm) and 37.7% (23/61 patients) in the presence of mitral valve disease (MVD), whereas the conversion rate was 82.5% (33/40 patients) in the absence of MVD and 85% (29/34 patients) in the absence of both enlarged LA and MVD (p =< 0.001). Patients with coronary artery disease (CAD) also exhibited a significantly greater response to ibutilide than patients without CAD (77 vs. 46%, p‐value 0.005).

Conclusion: As a therapy for cardioversion of AF, ibutilide is most effective in a selected subgroup patients, such as in patients with CAD and in patients without MVD and/ormarkedly enlarged left atrium.

Keywords: ibutilide, atrial fibrillation

Full Text

The Full Text of this article is available as a PDF (69.1 KB).

References

  • 1. Gilligan DM, Ellenbogen KA, Epstein AE: The management of atrial fibrillation. Am J Med 1996; 101:413–21 [DOI] [PubMed] [Google Scholar]
  • 2. Reardon M, Camm AJ: Atrial fibrillation in the elderly. Clin Cardiol 1996; 19(10): 765–775 [DOI] [PubMed] [Google Scholar]
  • 3. Camm AJ, Obel OA: Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol 1996; 78(8A): 3–11 [DOI] [PubMed] [Google Scholar]
  • 4. Obel OA, Camm AJ: The use of drugs for cardioversion of recent onset atrial fibrillation and flutter. Focus on ibutilide. Drugs 1998; 12(6): 461–476 [DOI] [PubMed] [Google Scholar]
  • 5. Kannel WB, Abott RD, Savage DD, McNamara PM: Coronary heart diseases and atrial fibrillation: The Framingham study. Am Heart J 1983; 106;389–396 [DOI] [PubMed] [Google Scholar]
  • 6. Wyse DG, Andersen JL, Antman EM, Cooper ES, Dalquist JE, Davis KB, Green HL, Mickel MC, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Shih JH, Epstein EA, Gersh J, Jenkins JL, Saksena S, Sherman DG, Steinberg JS: Atrial fibrillation followup investigation of rhythm management–The AFFIRM study design. Am J Cardiol 1997; 79:1198–1202 [PubMed] [Google Scholar]
  • 7. Viskin S, Barron HV, Heller K, Scheinman MM, Olgin JE: The treatment of atrial fibrillation: Pharmacologic strategies. Curr Probl Cardiol 1997; 22(2): 44–72 [DOI] [PubMed] [Google Scholar]
  • 8. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation: A study in awake, chronically instrumented goats. Circulation 1995; 92:1954–1968 [DOI] [PubMed] [Google Scholar]
  • 9. Zipes DP: Electrophysiological remodeling of the heart owing to rate. Circulation 1997; 95:1745–1748 [DOI] [PubMed] [Google Scholar]
  • 10. Prystowsky EN: Management of atrial fibrillation: Therapeutic options and clinical decisions. Am J Cardiol 2000; 85:3D–1 1D [DOI] [PubMed] [Google Scholar]
  • 11. Talajic M, MacDonald RG, Nattel S: Restoration of sinus rhythm in patients with atrial fibrillation. Can J Cardiol 1996; 12(suppl A): 29A–35A [PubMed] [Google Scholar]
  • 12. Zipes DP: Atrial fibrillation: A review of pathophysiology. Semin Intervent Cardiol 1997; 2:203–213 [PubMed] [Google Scholar]
  • 13. Waktare JEP, Camm AJ: Acute treatment of atrial fibrillation: Why and when to maintain sinus rhythm. Am J Cardiol 1998; 81(5A): 3C–15C [DOI] [PubMed] [Google Scholar]
  • 14. Califf RM: What to do with acute atrial fibrillation? Am Heart J 1999; 137(4Pt 1): 601–602 [DOI] [PubMed] [Google Scholar]
  • 15. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997; 54(2): 312–330 [DOI] [PubMed] [Google Scholar]
  • 16. Granberry MC: Ibutilide: A new class III antiarrhyhmic agent. Am J Health Syst Pharm 1998; 55(3): 255–260 [DOI] [PubMed] [Google Scholar]
  • 17. Murray KT: Ibutilide. Circulation 1998; 97(5): 493–97 [DOI] [PubMed] [Google Scholar]
  • 18. Sager PT: New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol 1999; 14(1): 15–23 [DOI] [PubMed] [Google Scholar]
  • 19. Capucci A, Villani GQ, Aschieri D, Piepoli M: Effects of Class III drugs on atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9(8 suppl): S109–120 [PubMed] [Google Scholar]
  • 20. Howard PA: Ibutilide: An antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother 1999; 33(1): 38–47 [DOI] [PubMed] [Google Scholar]
  • 21. Kowey PR, VanderLugt JT, Luderer JR: Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 1996; 78(8A): 46–52 [DOI] [PubMed] [Google Scholar]
  • 22. Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ: Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998; 31:588–592 [DOI] [PubMed] [Google Scholar]
  • 23. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC, Meissner MD, Zoble RG, Wakefield LK, Perry KT, Vanderlugt JT: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose‐response study. J Am Coll Cardiol 1996; 28:130–136 [DOI] [PubMed] [Google Scholar]
  • 24. Singh BN: Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 1998; 81(6A): 3D–13D [DOI] [PubMed] [Google Scholar]
  • 25. Foster RH, Wilde MI, Markhani A: Ibutilide: A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997; 54(2): 312–333 [DOI] [PubMed] [Google Scholar]
  • 26. Yang T, Snyders DJ, Roden DM: Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+current (Ikr)in AT‐1 cells. Circulation 1995; 91:1799–1806 [DOI] [PubMed] [Google Scholar]
  • 27. Jung F, DiMarco JP: Treatment strategies for atrial fibrillation. Am J Med 1998; 104:272–286 [DOI] [PubMed] [Google Scholar]
  • 28. Kowey PR, Marinchak RA, Rials SJ, Filart RA: Acute treatment of atrial fibrillation. Am J Cardiol 1998; 81(5A): 16C–22C [DOI] [PubMed] [Google Scholar]
  • 29. Ellenbogen KA, Clemo HF, Stamber BS, Wood MA, Vanderlugt JT: Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol 1996; 78(suppl 8A): 42–45 [DOI] [PubMed] [Google Scholar]
  • 30. Costeas C, Kassotis J, Blitzer M, Reiffel JA: Rhythm management in atrial fibrillation–with a primary emphasis on pharmacological therapy: Part 2. PACE 1998; 21(Pt. I): 742–752 [DOI] [PubMed] [Google Scholar]
  • 31. Luderitz B, Pfeiffer D, Tebbenjohanns J, Jung W: Nonpharmacologic strategies for treating atrial fibrillation. Am J Cardiol 1996; 77:45A–52A [DOI] [PubMed] [Google Scholar]
  • 32. Mittal S, Lerman BB: Current strategies for managing atrial fibrillation. Intern Med 1998; 19(2): 23–28 [Google Scholar]
  • 33. Anderson JL: Acute treatment of atrial fibrillation and flutter. Am J Cardiol 1996; 78(8A): 17–21 [DOI] [PubMed] [Google Scholar]
  • 34. Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F: Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340(24): 1849–1854 [DOI] [PubMed] [Google Scholar]
  • 35. Gelder ICV, Crijns HJ, Gilst WHV: Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct‐current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68:41–46 [DOI] [PubMed] [Google Scholar]
  • 36. Nabih MA, Prcevski P, Fromm BS, Lavine SJ, Elnabtity M, Munir A, Steinman RT, Meissner MD, Lehmann MH: Effect of ibutilide, a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. PACE 1993; 16:1975–1983 [DOI] [PubMed] [Google Scholar]
  • 37. VanderLugt JT, Mattioni T, Denker S, Torchiana D, Ahern T, Wakefield LK, Perry KT, Kowey PR: Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999; 100(4): 369–375 [DOI] [PubMed] [Google Scholar]
  • 38. Zaqqa M, Afshar H, Rakesh A, Khoshmevis R, Vaughn WK, Massumi A: Predictors of conversion to sinus rhythm using ibutilide for atrial fibrillation or flutter. Am J Cardiol 2000; 85:112–113 [DOI] [PubMed] [Google Scholar]
  • 39. Bharucha DB, Kowey PR: Management and prevention of atrial fibrillation after cardiovascular surgery. Am J Cardiol 2000; 85:20D–24D [DOI] [PubMed] [Google Scholar]
  • 40. Eversole A, Hancock W, Johns T, Lopez LM, Conti CR: Ibutilide: Efficacy and safety in atrial fibrillation and atrial flutter in general cardiology practice. Clin Cardiol 2001; 24:521–525 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES